The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports

• Published in: Alimentary pharmacology & therapeutics Vol. 31; no. 12; pp. 1337 - 1345
• Main Authors: LLANOS, L., MOREU, R., ORTIN, T., PEIRÓ, A. M., PASCUAL, S., BELLOT, P., BARQUERO, C., FRANCÉS, R., SUCH, J., PÉREZ‐MATEO, M., HORGA, J. F., ZAPATER, P.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.06.2010; Blackwell; Wiley Subscription Services, Inc; Wiley
• Subjects: Alanine; Alanine transaminase; Alanine Transaminase - blood; Biological and medical sciences; Biomarkers - blood; Black boxes; Case reports; Chemical and Drug Induced Liver Injury - enzymology; Clinical trials; Clinical Trials as Topic; Digestive system; Drug Labeling; Drugs; Gastroenterology. Liver. Pancreas. Abdomen; Hepatotoxicity; Humans; Incidence; Labeling; Liver; Medical sciences; Periodicals as Topic; Pharmacology. Drug treatments; Product Surveillance, Postmarketing; Publication Bias; Safety-Based Drug Withdrawals; Case study; Human; Biological fluid; Digestive system; Enzyme; Toxicity; Transaminases; Transferases; Liver; Alanine transaminase; Clinical trial; Serum; Medicine
• ISSN: 0269-2813; 1365-2036
• DOI: 10.1111/j.1365-2036.2010.04298.x

Aliment Pharmacol Ther 31, 1337–1345 Summary Background  Drug‐induced liver injury (DILI) profile in most drugs’ available information is based on both the incidence of alanine aminotansferase (ALT) elevations in clinical trials and published case reports. Aim  To assess the relationship between ALT elevations in clinical trials and the number of published case reports in the postmarketing setting. Methods  Hepatotoxic drugs were identified from product labelling and classified in high‐medium risk (Black Box Warning or Precautions section) or low risk (a statement in the Adverse Reactions section). Incidence of ALT elevations (≥3 × ULN) for drug (ID) and placebo (IC) treated patients in premarketing clinical trials and DILI published case reports were retrieved from product labelling and MEDLINE. Results  The median IC was 10/1000. The high‐medium‐risk drugs’ median ID was significantly higher compared with low‐risk drugs (17/1000 vs. 10/1000; P = 0.046). Chi‐squared test, absolute difference and odds ratio comparing ID and IC identified 35%, 51% and 77% of high‐medium‐risk drugs respectively. Less number of case reports were associated with low‐ than high‐medium‐risk drugs (1 vs. 7; P = 0.001). A high odds ratio in clinical trials (ID vs. IC) was the strongest predictor of published DILI case reports. Conclusion  A relationship between increased ALT incidence in premarketing clinical trials and postmarketing published case reports exists.